Oxford Nanopore Launches Flongle for Rapid, Smaller DNA/RNA Sequencing Tests in Any Environment

Food and Healthcare Press Releases Wednesday March 13, 2019 08:37
OXFORD, England--13 Mar--PRNewswire/InfoQuest

Oxford Nanopore has today made Flongle starter packs available to purchase https://store.nanoporetech.com/flongle.html, after initial testing in an early-access programme. Flongle introduces a new paradigm of smaller, on-demand DNA or RNA sequencing tests, with the potential to transform a range of applications where rapid insights are required at low cost.

Oxford Nanopore's goal is to enable the analysis of any living thing, by anyone, anywhere. Flongle is designed to bring this goal closer and to also allow low-cost sequencing at any time. With its compact format, Flongle opens up possibilities of on-demand testing in a broad range of locations, from scientific laboratories to farms and factories, healthcare settings, outdoor environments or classrooms.

Flongle is an adapter for the portable MinION and desktop GridION X5 sequencing devices. It uses the same core nanopore sequencing technology as other Oxford Nanopore devices, producing real-time data, direct sequencing and long reads. The small Flongle flow cells can currently produce as much as 1.8 Gb of sequence data with headroom for more than 3 Gb. This enables many sequencing experiment types, including small-genome sequencing, targeted panels/amplicon sequencing, metagenomics for the identification of viruses, bacteria or characterisation of microbiomes, or species ID. It can also be used for quality control for larger nanopore experiments.

At $90 per flow cell, Flongle allows on-demand sequencing at an affordable price point, without needing to wait for the large batches of samples that are often required to achieve low per-test costs on traditional sequencing devices. The workflow is fast and simple, with library preparation in as little as ten minutes and real-time data analysis.

Dr Matt Loose, from DeepSeq, School of Life Sciences, University of Nottingham, has been testing the Flongle as part of an early access programme. "We've been using Flongle for testing and developing new protocols such as CRISPR/Cas9 selection for targeting select regions of the human genome, as well as working up new samples before running at scale on PromethION. We've been very happy with throughput and yield on early access flow cells and are looking forward to incorporating production-ready Flongle into our workflows. It will be really interesting to see how users apply Flongle in the field."


Miten Jain, from the University of California, Santa Cruz, has also been trialling Flongle: "Flongle-based sequencing is the best way to check a nanopore library. At UC Santa Cruz, we now routinely sequence native RNA and genomic DNA libraries on a Flongle Flow Cell before scaling them to our PromethION. We have observed that Flongle-based sequencing is a good predictor of library quality and its performance on the PromethION. Flongle also permits experimental tests at a more affordable scale and will be an integral part of our nanopore work going forward."

Dr Justin O'Grady is a translational researcher from University of East Anglia, UK. He has been developing nanopore-based research methods for the rapid metagenomic characterisation of pathogens in clinical samples from patients with pneumonia or urinary tract infections. "I am excited about how Flongle can help identify pathogens and antimicrobial resistance more quickly, and how such technologies could be used in settings much closer to patients in the future."


Flongle starter packs are now available in store. These starter packs include the Flongle adapter and users can choose to run these on their MinION or GridION devices. Users will be able to purchase additional flow cells for $90 each. Protocols are being made available and use the current preparation kits already compatible with MinION, GridION and PromethION.

Oxford Nanopore is now taking pre-orders for the MinION Mk1C https://nanoporetech.com/products/minion-mk1c, which combines the real-time, portable sequencing of MinION with powerful computing and a high-resolution touchscreen. This device will be compatible with Flongle enabling rapid, field-based analyses; more information will be provided soon.

Video - https://mma.prnewswire.com/media/834428/Oxford_Nanopore_Flongle.mp4
Photo - https://mma.prnewswire.com/media/834426/Oxford_Nanopore_Flongle.jpg
Contact: Zoe McDougall, media@nanoporetech.com

Latest Press Release

Novo Nordisk (Thailand) is hosting a press conference for the topic of Rethink Obesity.

Mr. John Dawber, Vice President and General Manager at Novo Nordisk (Thailand) is hosting a press conference for the topic of "Rethink Obesity". The event will be chaired by His Excellency Mr. Uffe Wolffhechel, Ambassador of Denmark to Thailand, and will...

Brain Health Supplements Market Expecting an Outstanding Growth Till 2025

The global brain health supplements market size is expected to reach USD 10.7 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 8.2% over the forecast period. Growing health concerns over depression, anxiety,...

Menarini Silicon Biosystems Launches VRNxT Volume Reduction Instrument

Menarini Silicon Biosystems, the pioneer of liquid biopsy and rare cell technologies, announced that it will launch the new VRNxT(TM), a volume reduction instrument optimized to remove manual sample volume reduction steps in cellular biology...


The "6 months mother's milk is all you need" campaign has been awarded South East Asia PR Campaign of the year and Cause related public awareness campaign of the Year by Campaign Asia at the PR awards in Hong Kong last month. Initiated by Save The...

Daewoong Pharmaceutical participated in the IMCAS Asia 2019 to introduce the excellence of NABOTA

Daewoong Pharmaceutical Co., Ltd, a world-leading botulinum toxin manufacturer in Korea, announced its participation in IMCAS Asia 2019 held in Bali, Indonesia July 5-7, 2019 to introduce the excellence of NABOTA(R) (Prabotulinumtoxin A). The 13th year...

Related Topics